Currency In USD
| Previous Close | 364.58 |
| Open | 370.35 |
| Day High | 387.83 |
| Day Low | 366.12 |
| 52-Week High | 392.7 |
| 52-Week Low | 37.19 |
| Volume | 408,260 |
| Average Volume | 507,137 |
| Market Cap | 10.48B |
| PE | -29.08 |
| EPS | -12.93 |
| Moving Average 50 Days | 323.91 |
| Moving Average 200 Days | 298.78 |
| Change | 11.36 |
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 09, 2026 9:01 PM GMT
BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial resul
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy
GlobeNewswire Inc.
Jan 13, 2026 9:30 PM GMT
BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced the appointment of world-renowned
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress
GlobeNewswire Inc.
Jan 12, 2026 1:00 PM GMT
Two NDA submissions expected by mid-February 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs, both with Breakthrough Therapy Designation from the FDA Multiple registrational readouts expected across vormatrigine, relutrig